BCAX (Bicara Therapeutics) Capex-to-Operating-Income : 0.00 (As of Dec. 2024)

View and export this data going back to 2024. Start your Free Trial

What is Bicara Therapeutics Capex-to-Operating-Income?

Capex-to-Operating-Income measures a company's investments in physical assets such as property, industrial buildings or equipment to its operating income.

Bicara Therapeutics's Capital Expenditure for the three months ended in Dec. 2024 was $-0.04 Mil. Its Operating Income for the three months ended in Dec. 2024 was $-26.64 Mil.

GuruFocus do not calculate Capex-to-Operating-Income if the Operating Income is negative.

Bicara Therapeutics Capex-to-Operating-Income Historical Data

The historical data trend for Bicara Therapeutics's Capex-to-Operating-Income can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Bicara Therapeutics Capex-to-Operating-Income Chart

Bicara Therapeutics Annual Data

Trend

Dec22

Dec23

Dec24

Capex-to-Operating-Income

Bicara Therapeutics Quarterly Data
	Dec22	Sep23	Dec23	Jun24	Sep24	Dec24
Capex-to-Operating-Income	Get a 7-Day Free Trial			-	-	-	-	-

Competitive Comparison of Bicara Therapeutics's Capex-to-Operating-Income

For the Biotechnology subindustry, Bicara Therapeutics's Capex-to-Operating-Income, along with its competitors' market caps and Capex-to-Operating-Income data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Bicara Therapeutics's Capex-to-Operating-Income Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Bicara Therapeutics's Capex-to-Operating-Income distribution charts can be found below:

* The bar in red indicates where Bicara Therapeutics's Capex-to-Operating-Income falls into.

Save Embed

;

Save Embed

;

Bicara Therapeutics Capex-to-Operating-Income Calculation

Bicara Therapeutics's Capex-to-Operating-Income for the fiscal year that ended in Dec. 2024 is calculated as

Capex-to-Operating-Income	=	- Capital Expenditure	/	Operating Income
	=	- (-0.071)	/	-82.389
	=	N/A

Bicara Therapeutics's Capex-to-Operating-Income for the quarter that ended in Dec. 2024 is calculated as

Capex-to-Operating-Income	=	- Capital Expenditure	/	Operating Income
	=	- (-0.04)	/	-26.637
	=	N/A

Bicara Therapeutics (NAS:BCAX) Capex-to-Operating-Income Explanation

Capex-to-Operating-Income assesses how much emphasis a company is placing upon investing in capital-intensive projects. The ratio is generally a good gauge to quantify how much focus on growth a company has. Typically, smaller companies that are still growing and expanding will have a higher Capex to Operating Income Ratio, since such businesses are likely investing more in physical assets. Lower ratios could indicate that a company has reached maturity and it is no longer pursuing aggressive growth.

Bicara Therapeutics Capex-to-Operating-Income Related Terms

Thank you for viewing the detailed overview of Bicara Therapeutics's Capex-to-Operating-Income provided by GuruFocus.com. Please click on the following links to see related term pages.

Bicara Therapeutics Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Bicara Therapeutics Inc (NAS:BCAX) » Definitions » Capex-to-Operating-Income

Comparable Companies

Traded in Other Exchanges

N/A

Address

116 Huntington Avenue, Suite 703, Boston, MA, USA, 02116

Website

https://www.bicara.com

Bicara Therapeutics Inc is a clinical-stage biopharmaceutical company bringing transformative bifunctional therapies to patients with solid tumors. Its program ficerafusp alfa is a bifunctional antibody that combines two clinically validated targets, an epidermal growth factor receptor, or EGFR, directed monoclonal antibody with a domain that binds to human transforming growth factor beta, or TGF-b.